ClinicalTrials.gg

Program

Isosorbide

Also written as “Isosorbide oral solution”, “AT101(Anti-CD19 Chimeric Antigen Receptor T cell)” and “Isobide”.

Its studies are mostly in Hearing Loss · Lymphoma, B-Cell · Meniere Disease, led by 3 companies.

Furthest: phase 4, since Apr 1, 20223 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbClon11 open or runningphase 2since Apr 1, 2022Apr 1, 2022Mar 15, 2030phase 2 · NCT05338931
Lotus Pharmaceutical10 open or runningphase 4since Mar 21, 2016Mar 21, 2016none ahead
Lunan Pharmaceutical Group11 open or runningphase 3since Dec 23, 2024Dec 23, 2024Jun 30, 2027phase 3 · NCT06765993

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 21, 2016First study: phase 4 study in Meniere DiseaseNew to Lotus PharmaceuticalLotus Pharmaceutical · NCT02718846 · 220 enrolled
  2. Apr 1, 2022AbClon's first study: phase 2 study in Lymphoma, B-CellNew to AbClonAbClon · NCT05338931 · 82 planned · Korea, Republic of
  3. Dec 23, 2024Lunan Pharmaceutical Group's first study: phase 3 study in Hearing LossNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06765993 · 234 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Hearing LossLunan Pharmaceutical Group · NCT06765993
  2. Mar 15, 2030Primary completion: phase 2 study in Lymphoma, B-CellAbClon · NCT05338931

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06765993Hearing Loss3Not yet recruitingLunan Pharmaceutical GroupJun 30, 2027234
NCT05338931Lymphoma, B-Cell · Korea, Republic of2RecruitingAbClonMar 15, 203082
NCT02718846Meniere Disease4CompletedLotus PharmaceuticalMay 2015220

How it is read

Names in the registry

  • “Isosorbide oral solution”, 1 entry
  • “AT101(Anti-CD19 Chimeric Antigen Receptor T cell)”, 1 entry
  • “Isobide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.